Science Without Boundaries: Metastatic NSCLC Highlights from WCLC 2026

The International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC) brought the global thoracic oncology community to Seoul, Republic of Korea, from September 12–15. This year's theme, "Science Without Boundaries: Uniting the World Against Thoracic Cancer," was truly fitting for a meeting where research from Asia, Europe, and the Americas shaped the conversation around approaches to treating metastatic/advanced non-small cell lung cancer (NSCLC). Longer survival follow-up, new first-line options for rare mutations, and a growing focus on healthcare

EGFR in 2026: What’s New and What’s Next

LUNGevity offers a variety of virtual support groups called ‘meetups’ where survivors and caregivers impacted by lung cancer connect with others who understand the patient experience. Once a month, we invite an expert to share information on a topic related to life with lung cancer, engage with attendees, and answer questions in real time. Visit the LUNGevity Calendar to see upcoming events like this one. In September, we were joined by Dr. Benjamin Levy, MD, thoracic medical oncologist and clinical director of medical oncology for the Johns Hopkins Sidney Kimmel Cancer Center at Sibley

Science Without Boundaries: Small Cell Lung Cancer Highlights from WCLC 2026

The 2026 World Conference on Lung Cancer (WCLC) brought the global thoracic oncology community to Seoul, South Korea from September 12–15. This year's theme, "Science Without Boundaries: Uniting the World Against Thoracic Cancer," was particularly fitting for small cell lung cancer (SCLC). Data from two exciting phase 3 clinical trials were discussed as part of the conference’s plenary sessions and we saw scientific progress across every part of the patient journey. Here are the conference highlights, organized by limited-stage (LS) and extensive-stage (ES) disease. Limited-Stage SCLC Can we

Small Cell SMASHERS Fireside Chat with Dr. Benjamin Morris

In September, we were joined by Benjamin Morris, MD, CPRIT TRIUMPH postdoctoral fellow at UT MD Anderson Cancer Center. Dr. Morris discussed his research, the IASCLC Young Investigators group, and how their work can help those with SCLC. Moderated by Misty Shields, MD, PhD, Indiana University School of Medicine, and LUNGevity’s Ann Steagall, SVP of Patient Services and Health Care Delivery, this monthly virtual series highlights the latest discoveries and breakthroughs for SCLC.

Small Cell SMASHERS Fireside Chat with Dr. Jacob Sands

In August, we were joined by Jacob Sands, MD, Associate Chief of the Lowe Center for Thoracic Oncology and Assistant Professor of Medicine at Harvard Medical School. Dr. Sands discussed The Importance of HOPE: Highlighting Recent Advancements in SCLC. Moderated by Misty Shields, MD, PhD, Indiana University School of Medicine, and LUNGevity’s Upal Basu Roy, PhD, MPH, Executive Director of Research, this monthly virtual series highlights the latest discoveries and breakthroughs for SCLC.

Real Progress and Real Gaps: Highlights of the 2026 AACR Disparities Report

I have spent my career focused on the intersection between cancer research and public health. Since joining LUNGevity over a decade ago, it has been nothing short of a privilege to witness how research has changed how we diagnose and treat lung cancer. We have seen unimaginable improvements in the field. However, this scientific progress seems to have outpaced our ability to effectively deliver these benefits to all patients. Key questions remain: Is every person at an increased risk of developing lung cancer getting screened? Is every person diagnosed with lung cancer receiving the best

Small Cell SMASHERS Fireside Chat with Dr. Charles Rudin

In June, we were joined by Charles Rudin, MD, PhD, Memorial Sloan Kettering Cancer Center. Dr. Rudin discussed how participation in clinical trials has brought hope and meaningful change for people with SCLC. Moderated by Misty Shields, MD, PhD, Indiana University School of Medicine, and LUNGevity’s Ann Steagall, SVP of Patient Services and Health Care Delivery, this monthly virtual series highlights the latest discoveries and breakthroughs for SCLC.

Top Lung Cancer Research Highlights from ASCO 2026

Each year, the American Society of Clinical Oncology (ASCO) Annual Meeting brings together the world’s largest gathering of the oncology community. Approximately 40,000 researchers, physicians, nurses, advocates, biotech and pharmaceutical professionals, and others, meet annually to discuss research that shapes how cancer is diagnosed, treated, and managed. The 2026 meeting took place May 29 - June 2 in Chicago and included important advances in lung cancer treatment. We saw awe-inspiring long-term results from a targeted therapy, new approaches for patients with specific biomarkers

Precision, Partnership, Purpose: Lung Cancer Highlights from AACR 2026

The American Association for Cancer Research (AACR) Annual Meeting brought together thousands of cancer researchers, clinicians, advocates, and patients in San Diego from April 17–22. This year's theme—“Precision, Partnership, Purpose: Advancing Cancer Science to Save Lives Globally”—set a powerful tone for a meeting that showcased advances across the lung cancer landscape. One message was loud and clear. Science is accelerating, and we are reimagining how healthcare is delivered. From next-generation targeted therapies to AI-powered diagnostics, AACR 2026 offered a snapshot of both the

Small Cell SMASHERS Fireside Chat with Dr. Simon Heeke

In May, we were joined by Simon Heeke, PhD, MD Anderson Cancer Center. Dr. Heeke discussed biomarker identification and their potential roles in patients impacted by SCLC. Moderated by Misty Shields, MD, PhD, Indiana University School of Medicine, and LUNGevity’s Ann Fish-Steagall, SVP of Patient Services and Health Care Delivery, this monthly virtual series highlights the latest discoveries and breakthroughs for SCLC.